Alena J Markmann, D Ryan Bhowmik, Baowei Jiang, Usaphea P Vanna, Michael Van Hoy, Frank Wang, Yixuan J Hou, David M Margolis, Ralph S Baric, Aravinda M de Silva, Luther A Bartelt
{"title":"A Novel Adaptive Platform for Rapid, Simple Flow-Based Antibody Detection Devices Predicts NAb Levels to SARS-CoV-2.","authors":"Alena J Markmann, D Ryan Bhowmik, Baowei Jiang, Usaphea P Vanna, Michael Van Hoy, Frank Wang, Yixuan J Hou, David M Margolis, Ralph S Baric, Aravinda M de Silva, Luther A Bartelt","doi":"10.20411/pai.v11i1.910","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 has caused millions of deaths and continues to burden individuals and the healthcare system. Antibodies that neutralize SARS-CoV-2 have proven to be the most reliable markers of immune protection, targets for vaccine development, and approaches for anti-viral antibody-based therapies. Measuring neutralizing antibody (NAb) titers at the bedside could inform individualized shared decision-making with patients regarding the potential benefits of repeating vaccines, use of preventative or therapeutic antibody-based therapies, and, where relevant, collection of COVID-19 convalescent plasma (CCP) with greater efficacy, especially as NAb-escape mutations have guided SARS-CoV-2 variant emergence. However, specific and accessible assays to quantify NAb levels in individuals, including the identification of potential antibody donors at the time of donation, remain unavailable. Therefore, there is a need for platforms that can be rapidly adapted to quantify serum antibody responses with known or expected correlates of protection.</p><p><strong>Methods: </strong>In this report, we apply a novel semi-quantitative method to an established antibody lateral flow assay (sqLFA) and analyze its ability to detect the presence of functional NAbs in the serum of COVID-19-recovered individuals early in the pandemic.</p><p><strong>Results: </strong>We found that the sqLFA has a strong positive correlation with the gold-standard microneutralization assay (specificity 80% and sensitivity 90% at a microneutralization cutoff of 1:40).</p><p><strong>Conclusions: </strong>Taken together, the sqLFA provides a novel point-of-care-based platform for rapid readout of NAb-based immune protection to SARS-CoV-2.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"11 1","pages":"96-110"},"PeriodicalIF":0.0000,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928283/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and Immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20411/pai.v11i1.910","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: COVID-19 has caused millions of deaths and continues to burden individuals and the healthcare system. Antibodies that neutralize SARS-CoV-2 have proven to be the most reliable markers of immune protection, targets for vaccine development, and approaches for anti-viral antibody-based therapies. Measuring neutralizing antibody (NAb) titers at the bedside could inform individualized shared decision-making with patients regarding the potential benefits of repeating vaccines, use of preventative or therapeutic antibody-based therapies, and, where relevant, collection of COVID-19 convalescent plasma (CCP) with greater efficacy, especially as NAb-escape mutations have guided SARS-CoV-2 variant emergence. However, specific and accessible assays to quantify NAb levels in individuals, including the identification of potential antibody donors at the time of donation, remain unavailable. Therefore, there is a need for platforms that can be rapidly adapted to quantify serum antibody responses with known or expected correlates of protection.
Methods: In this report, we apply a novel semi-quantitative method to an established antibody lateral flow assay (sqLFA) and analyze its ability to detect the presence of functional NAbs in the serum of COVID-19-recovered individuals early in the pandemic.
Results: We found that the sqLFA has a strong positive correlation with the gold-standard microneutralization assay (specificity 80% and sensitivity 90% at a microneutralization cutoff of 1:40).
Conclusions: Taken together, the sqLFA provides a novel point-of-care-based platform for rapid readout of NAb-based immune protection to SARS-CoV-2.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
